MRKR

Business Context and Reporting Period

Company: Marker Therapeutics, Inc. (MRKR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: A clinical-stage immuno-oncology company developing multi tumor associated antigen (multiTAA)-specific T cell therapies for hematological malignancies and solid tumors. The company operates without product sales revenue, relying on grants and financing.

Key Financial Metrics

Note: The company reported no discontinued operations activity for the current period. Prior year comparisons include significant gains from the sale of manufacturing assets to Cell Ready, LLC.

Material Changes vs. Prior Period

• Revenue Growth: Grant income increased 53% year-over-year for the quarter ($1.17M vs. $0.76M) and 21% for the six-month period ($2.41M vs. $2.00M), driven by recognition of funds from CPRIT, FDA, and SBIR grants.
• Expense Reduction: Total operating expenses decreased 29% for the quarter and 30% for the six-month period compared to the prior year. General and Administrative (G&A) expenses dropped significantly (55% and 50% respectively) due to reduced headcount and lower stock-based compensation.
• Cash Position: Cash and cash equivalents declined from $15.1 million at year-end 2023 to $7.8 million at June 30, 2024, reflecting a net cash burn of approximately $7.3 million from continuing operations over the six-month period.
• Discontinued Operations: Unlike the prior year, which included an $8.8 million gain on the disposal of manufacturing assets to Cell Ready, the current period had no activity in discontinued operations.

Outlook, Risks, and Management Commentary

• Liquidity Outlook: Management estimates that current cash balances ($7.8M) combined with available grant drawdowns will fund operations into the fourth quarter of 2025. The company does not expect to generate substantial revenue from product sales in the near term.
• Financing Actions: The company terminated its At-The-Market (ATM) equity offering agreement with Cantor Fitzgerald and RBC Capital Markets on June 10, 2024, to explore more effective market access strategies. It also terminated a stock purchase agreement with Lincoln Park Capital Fund in March 2024.
• Related Party Transactions: The company entered a Master Services Agreement (MSA) with Cell Ready, LLC (owned by a director/shareholder) to outsource manufacturing and R&D services. Expenses related to Cell Ready totaled $1.84 million for the six months ended June 30, 2024.
• Risks: The company faces risks related to its ability to raise additional capital, the success of clinical trials for MT-401 and MT-601, and reliance on grant funding. Macroeconomic factors such as inflation and market volatility may impact capital access.
• Recent Developments: In August 2024 (subsequent event), the company was awarded a $2.0 million NIH SBIR grant for MT-601 clinical investigation.

Investor Verification Checklist

• Cash Runway: Verify the timeline for funding into Q4 2025 against actual burn rates and the timing of grant disbursements.
• Grant Receivables: Confirm the collectability of the $2.3 million in grant income receivables recorded as of June 30, 2024 (CPRIT, FDA, SBIR).
• Related Party Costs: Review the terms and pricing of the Master Services Agreement with Cell Ready, LLC to ensure costs are at arm's length.
• Capital Raising Strategy: Assess the company's plan to replace the terminated ATM facility and secure future financing given the lack of product revenue.
• Clinical Progress: Monitor updates on the APOLLO study and the status of MT-401 and MT-601 clinical trials.